drugset / Trial / NCT00930332

Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain

NCT00930332

Phase 1 Terminated 8 enrolled NCIC Clinical Trials Group
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Methadone hydrochloride may reduce chronic neuropathic pain in patients with cancer. PURPOSE: This phase I trial is studying the side effects and best dose of methadone hydrochloride as first-line therapy in treating patients with chronic neuropathic cancer pain.

Timeline

Start
2010-06-17
Primary completion
2012-01-06
Completion
2012-01-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methadone Other / unclassified 1 mg Oral
Comparator Methadone Other / unclassified 2 mg Oral
Comparator Methadone Other / unclassified 3 mg Oral
Comparator Methadone Other / unclassified 4 mg Oral